A Venture Capital firm based in the US seeks to invest in transformational healthcare, focused on diseases of aging. The fund’s investment strategy is to initially invest in Seed-Series A rounds in the range of $1M-$4M and then provide capital throughout the company’s life via additional investments. In terms of capital structure, the firm prefers to participate in priced equity rounds, however convertible notes or other structures may be considered. The firm will act as a lead, co-lead or follow-on investor depending on the nature/terms of the deal and other investors participating in the round.
The firm is interested in disruptive technologies that target extreme inefficiencies in the healthcare system, such as digital health solutions based on artificial intelligence or big data platforms, as well as cutting-edge technologies at the intersection of multiple disciplines (eg physics and biology). The firm is not interested in traditional medical devices and diagnostics, but rather devices or diagnostics whose core IP lies within the underlying platform technology or software.
The firm is open to companies globally but prefers to invest in companies based in the US. Typically, companies that aren’t located in the U.S. would need to have some operations based in the United States. Emphasis is placed on the strength of the management team when making an investment decision, and the firm seeks to work with entrepreneurs who have a strong understanding of their market and sound logic behind why their vision and business model will be successful. Although successful, repeat entrepreneurs are highly valued, The firm will work with entrepreneurs of all experience levels. Board seats are not required along with an investment but may be appropriate depending on the deal structure.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment